Genetic Information for Families After Tumor Testing Study

Enrolling by invitation · Not applicable

Conditions studied: Cancer

In brief

The purpose of this study is to develop and implement a methodology of digital tools paired with telemedicine to improve cascade testing for clinically significant germline mutations among family members of children with cancer who have a pathogenic or likely pathogenic(P/LP) germline variant in a cancer predisposition gene.

Key facts

Study ID

NCT07517666

Run by

Abramson Cancer Center at Penn Medicine

People needed

100

Starts

2026-07-15

Expected to finish

2028-03-01

Last updated by the study team

2026-07-29

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Biological parent of a child enrolled in the ORIGen cohort (AEPI24N1) who has a confirmed P/LP germline variant in a CPG.
• 18 years of age or older.
• Speak and understand English.

You may not qualify if…

• Previous genetic testing for the familial variant.
• Communication difficulties such as:
• Uncorrected or uncompensated hearing and/or vision impairment. Patients who can successfully use clinical assistance devices are not excluded.
• Uncorrected or uncompensated speech defects. Patients who can successfully use clinical assistance devices are not excluded.
• Uncontrolled psychiatric/mental condition or severe physical, neurological or cognitive deficits rendering individual unable to understand study goals and tasks.

Where it is running

• University of Pennsylvania — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.